Supernus Pharmaceuticals (SUPN) Non-Current Deferred Tax Liability (2015 - 2025)

Supernus Pharmaceuticals (SUPN) has 8 years of Non-Current Deferred Tax Liability data on file, last reported at $981000.0 in Q1 2025.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 94.97% year-over-year to $981000.0 in Q1 2025; TTM through Mar 2025 was $981000.0, a 94.97% decrease from a year earlier, with the FY2024 full-year figure at $5.0 million, down 96.83% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2025 stood at $981000.0, down from $5.0 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for SUPN reached as high as $184.7 million in Q4 2022 and fell as low as $981000.0 in Q1 2025.
• Historically, Non-Current Deferred Tax Liability has averaged $51.7 million across 5 years, with a median of $35.2 million in 2023.
• Across the five-year window, Non-Current Deferred Tax Liability surged 116.37% in 2022 and tumbled 96.83% in 2024, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $85.4 million in 2021, then jumped by 116.37% to $184.7 million in 2022, then decreased by 15.39% to $156.3 million in 2023, then tumbled by 96.83% to $5.0 million in 2024, then tumbled by 80.23% to $981000.0 in 2025.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $981000.0 in Q1 2025, $5.0 million in Q4 2024, and $7.4 million in Q3 2024.